Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new imaging trick spot pancreatic cancer without a biopsy?

NCT ID NCT07763561

Diagnosis Sponsor: Julio Iglesias García Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study looks at whether a special ultrasound technique called detective flow imaging (DFI) can help doctors tell the difference between benign and malignant solid pancreatic lesions. Researchers will examine the blood vessel patterns seen with this technique and compare them to the final diagnosis from tissue samples or follow-up. The study involves 48 adults with solid pancreatic lesions and aims to see if this imaging method is accurate and consistent between different doctors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endoscopic ultrasound-guided detective flow imaging (EUS-DFI), an imaging technique
What this could lead to
If successful, this imaging method could improve how doctors tell benign from malignant pancreatic lesions without invasive biopsies, leading to faster and more accurate diagnoses.
What could go wrong
This is an observational study with a small number of participants, so results may not apply broadly. The technique's accuracy depends on operator skill, and it may not clearly distinguish all tumor types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients undergoing routine endoscopic ultrasound (EUS) in participating centers in whom a solid pancreatic lesion is identified and who provide written informed consent.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older. * Presence of a solid pancreatic lesion identified during endoscopic ultrasound (EUS), regardless of the indication for the examination. * Ability and willingness to provide written informed consent. Exclusion Criteria: * Predominantly cystic pancreatic lesions. * Anatomical abnormalities preventing adequate EUS examination. * Limited ability to understand the study procedures or provide informed consent. * Refusal to sign the informed consent form.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic neoplasms Pancreatic solid lesions

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.